ID   KINGS-1
AC   CVCL_1328
SY   Kings-1; KINGS1
DR   CLO; CLO_0009893
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 910
DR   BioSample; SAMN03470889
DR   cancercelllines; CVCL_1328
DR   Cell_Model_Passport; SIDM00612
DR   CGH-DB; 143-1
DR   ChEMBL-Cells; CHEMBL3308264
DR   ChEMBL-Targets; CHEMBL2366229
DR   Cosmic; 907279
DR   Cosmic; 2367531
DR   Cosmic-CLP; 907279
DR   DepMap; ACH-002257
DR   EGA; EGAS00001000978
DR   GDSC; 907279
DR   GEO; GSM1669986
DR   IARC_TP53; 21432
DR   JCRB; IFO50435
DR   LINCS_LDP; LCL-1381
DR   PharmacoDB; KINGS1_749_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1328
DR   Wikidata; Q54899934
RX   CelloPub=CLPUB00151;
RX   PubMed=16232199;
RX   PubMed=20164919;
RX   PubMed=25877200;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=73.94%; East Asian, South=26.06%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Caution: Indicated as originating from a 67 year old male patient in CelloPub=CLPUB00151 and from a 72 year old in JCRB=IFO50435.
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
ST   Source(s): Cosmic-CLP; JCRB; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8
ST   D16S539: 9,11
ST   D18S51: 18,26
ST   D19S433: 13,14
ST   D21S11: 30,31
ST   D2S1338: 17,19
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 10,12
ST   D8S1179: 11,16
ST   FGA: 23,24
ST   Penta D: 10,13
ST   Penta E: 16,25
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 14,17
DI   NCIt; C9477; Anaplastic astrocytoma
DI   ORDO; Orphanet_251589; Anaplastic astrocytoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   CelloPub=CLPUB00151;
RA   Iryo O.;
RT   "Establishment and characterization of a human glioma cell-line
RT   (KINGS-1) carrying leukocytes differentiation antigens.";
RL   J. Kurume Med. Assoc. 51:304-316(1988).
//
RX   PubMed=16232199; DOI=10.1111/j.1349-7006.2005.00099.x;
RA   Saigusa K., Hashimoto N., Tsuda H., Yokoi S., Maruno M., Yoshimine T.,
RA   Aoyagi M., Ohno K., Imoto I., Inazawa J.;
RT   "Overexpressed Skp2 within 5p amplification detected by array-based
RT   comparative genomic hybridization is associated with poor prognosis of
RT   glioblastomas.";
RL   Cancer Sci. 96:676-683(2005).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//